百奥泰：阿达木单抗注射液获得英国MHRA上市批准

Core Viewpoint - The company, Baiotai (688177.SH), has received marketing approval from the UK Medicines and Healthcare products Regulatory Agency (MHRA) for Qletli® (BAT1406, Adalimumab injection), which is expected to positively impact the company's long-term operational performance [1] Group 1 - The approval allows Qletli® to be sold in the UK, expanding the company's overseas product offerings [1] - The marketing authorization signifies a strategic milestone for the company in enhancing its market presence [1] - The introduction of Qletli® is anticipated to contribute positively to the company's revenue growth [1]